Skip to main content
Premium Trial:

Request an Annual Quote

Lion Takes Stake in E-Health Co. in Effort to Expand into Research, Diagnostics

NEW YORK, Feb 21 – Lion Bioscience said Wednesday it acquired a 16.1 percent stake in a German developer of e-health data management software in its latest move to expand its reach into medical research and diagnostics.

Lion paid 8.75 million euros ($7.99 million) for the stake in Gesellschaft f r Medizinische Datenverarbeitung and received an option to acquire an additional nine percent of the company’s equity. Lion has the option until June 30, 2002.

Lion said it would base its decision about whether to exercise the option on the outcome of a joint pilot project in which the two companies will develop software platforms for discovering the causes of diseases and explore opportunities for developing individualized diagnostics and therapies.

GMD of Munich develops medical information management technology that is used in French, German, and American hospitals. The company’s technology allows hospital staff to gather and manage medical records.

“In addition to the management of hospital data we will expand our solutions into the areas of clinical trials and integration of practicing doctors into this network,” Lutz Kleinholz, managing director of GMD, said in a statement. “With our platform as the basis we will then be able to transform our results directly from research into medicine.”

Over the past few months, Lion has taken several steps to increase its business beyond bioinformatics into drug discovery. In December, the Heidelberg, Germany-based company acquired Trega Biosciences, a cheminformatics firm that has developed tools to simulate how drug candidates are processed in humans.

In October, Lion also penned a deal with cheminformatics company Tripos to provide Bayer with an integrated bioinformatics and cheminformatics technology platform for drug discovery and agricultural chemical research. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.